Ark Therapeutics, a gene-based biopharmaceutical firm with operations in the UK and Finland, has a new head of business development.
Kassim Kolia has taken responsibility for building Ark’s manufacturing services business at its viral process development and manufacturing facility in Kuopio, Finland.
Kolia joins Ark from Eden Biodesign, part of Watson Pharmaceuticals, where, since 2006, he has been responsible for the business development of the firm’s contract development and manufacturing services.
Before joining Eden Biodesign, Kolia was key account manager at Bachem (UK), where he was responsible for business development of cGMP business opportunities in the UK and Ireland. Prior to this, he was cGMP line manager at Lonza Biologics, where he was responsible for the day-to-day running of the manufacturing plant.
